News Home

Is it Time to Dump Amyris Inc (AMRS) Stock After it Is Up 2.27% in a Week?

Friday, March 31, 2023 03:24 PM | InvestorsObserver Analysts

Mentioned in this article

Is it Time to Dump Amyris Inc (AMRS) Stock After it Is Up 2.27% in a Week?

Amyris Inc (AMRS) stock has risen 2.27% over the past week and gets a Neutral rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,neutral
Amyris Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on AMRS!

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With AMRS Stock Today?

Amyris Inc (AMRS) stock is lower by -0.74% while the S&P 500 is up 1.17% as of 3:23 PM on Friday, Mar 31. AMRS is lower by -$0.01 from the previous closing price of $1.36 on volume of 1,136,956 shares. Over the past year the S&P 500 is down -10.95% while AMRS is lower by -69.66%. AMRS lost -$1.65 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Amyris Inc click here.

More About Amyris Inc

Amyris Inc is an industrial biotechnology company. It is engaged in the engineering, manufacturing, and sales of products in a variety of consumer and industrial markets, including cosmetics, flavors and fragrances, solvents and cleaners, polymers, lubricants, healthcare products, and fuels. The business operations are spread across the world with the majority of the revenues generated in the United States. The company generates revenue from the sale of renewable products, licenses of and royalties from intellectual property, and grants, and collaborative research and development services. Click Here to get the full Stock Report for Amyris Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App